Dalbavancin: a new lipoglycopeptide antibiotic (Q37116602)

18 August 2017

1 reference

title

Dalbavancin: a new lipoglycopeptide antibiotic (English)

1 reference

18 August 2017

Jennifer Bailey

1

1 reference

18 August 2017

Kelly M Summers

series ordinal

2

1 reference

18 August 2017

publication date

1 April 2008

1 reference

American Journal of Health-System Pharmacy

18 August 2017

published in

1 reference

18 August 2017

volume

65

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

599-610

1 reference

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Antimicrobial Resistance in Streptococcus pneumoniae: An Overview

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin: Establishment of Endemicity in a University Medical Center

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Recent advances in the treatment of infections due to resistant Staphylococcus aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Epidemiological Profile of Linezolid‐Resistant Coagulase‐Negative Staphylococci

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986 to 2002.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Origin, structure, and activity in vitro and in vivo of dalbavancin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Antibacterial activities and modes of action of vancomycin and related glycopeptides

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Glycopeptides: Update on an old successful antibiotic class

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Pharmacokinetics and excretion of dalbavancin in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Effect of dalbavancin on the normal intestinal microflora.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070255

31 March 2020

Identifiers

DOI

10.2146/AJHP070255

1 reference

18 August 2017

1 reference